Merck Animal Health Expands NOBIVAC NXT Platform to Include Vaccine for Feline Leukemia Virus
Shots:
- Merck Animal Health has expanded the use of its NOBIVAC NXT vaccine platform to include a new vaccine for feline leukemia virus (FeLV), with its global availability anticipated in Sep 2024
- NOBIVAC NXT FeLV (low volume 0.5mL dose, 2 doses, 3-4wks. apart) is a nonadjuvanted vaccine intended to protect cats (≥8wks.) against feline leukemia virus (FeLV). It triggers a strong immune response while ensuring comfort and safety plus offers a 2-year duration of immunity
- NOBIVAC NXT FeLV is developed using Merck's RNA-particle technology platform to provide optimized protection. This technology was also utilized for developing NOBIVAC NXT Rabies and Canine Flu H3N2, launched in 2024
Ref: Merck Animal Health | Image: Merck Animal Health & Cambridge Technologies
Related News:- Merck Animal Health Reports the Accessibility of Autogenous Vaccine for Avian Metapneumovirus Type B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
